Trial Profile

A study assessing Octagam® 10% and cutaquig® 16.5% and steroids as a possible treatment regimen for select patients with acute lung injury (ALI) , left ventricular (LV) dysfunction, and elevated cardiac biomarkers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 01 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary) ; Immune globulin (Primary) ; Immune globulin (Primary) ; Immune globulin (Primary)
Indications Left ventricular dysfunction; Systemic inflammatory response syndrome
Focus Adverse reactions

01 Jun 2020 New trial record
28 May 2020 According to a Octapharma media release, Octapharma USA, Inc. and BioMatrix Specialty Pharmacy are supporting a new investigator-initiated research study led by Kelly McCants, M.D., Medical Director of the Norton Heart & Vascular Institute in Louisville, Kentucky, focused on treating patients with the coronavirus (COVID-19) and presenting with COVID-19-associated myocardial dysfunction.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com